DeCure for Chlamydia trachomatis infectious disease
DeCure's autonomous AMR AI scientist is researching a drug-repurposing hypothesis for Chlamydia trachomatis infectious disease — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChlamydia trachomatis infectious disease maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedDoxycyclineApproved drug
Structures already discussed alongside chlamydia trachomatis infectious disease in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Crystal structure of Alpha1-antichymotrypsin variant DBS-I1: a drug-binding serpin for doxycycline — Doxycycline has a real, experimentally solved structure in complex with this target (PDB 5OM2, 1.47 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet dxtdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5OM2 · 1.47 Å · ligand Doxycycline (DXT). Experimental structure, not a prediction.
What the evidence adds up to
Chlamydia trachomatis remains a strict intracellular human pathogen, the main bacterial cause of sexually transmitted infections and the aetiologic agent of trachoma, which is the leading cause of preventable blindness. Despite more than a century since its identification, no vaccine exists. A 2023 mini-review notes that recent advances in genetic manipulation have increased understanding of the molecular pathogenesis, but the review only outlines factors in the developmental cycle and specific pathogenesis activity — it does not report any clinical trial results or therapeutic interventions.
A 2021 study using genetic manipulation of C. trachomatis found that the type III secreted effector TmeA directly activates N-WASP to promote actin polymerisation and functions synergistically with another effector, TarP, during invasion. The authors state this provides definitive insight into TmeA’s role and implicates at least one source of functional divergence in entry mechanisms among chlamydial species. No patient data, survival figures, or response rates are reported; the work is entirely mechanistic and in vitro.
A 2025 comparative analysis of azithromycin and doxycycline for trachoma reviews efficacy, resistance data, administration methods, and current clinical application. The paper aims to reveal the advantages and limitations of the two drugs, but the abstract provides no concrete numbers — no response rates, no sample sizes, no survival data. It does not claim superiority for either drug, nor does it report any new trial results.
What is still missing is a vaccine, any clinical trial testing a repurposed drug against C. trachomatis infection, and patient-level outcome data from controlled studies. The mechanistic work on TmeA and TarP has not been translated into a therapeutic candidate, and the comparative drug review offers no new evidence to guide treatment choice. Funding for translational research, a properly designed randomised trial comparing existing antibiotics with novel agents, and stratification of patients by infection site or antibiotic resistance profile remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
mBio · 2021 · 39 citations · open access
Chlamydia trachomatis TmeA Directly Activates N-WASP To Promote Actin Polymerization and Functions Synergistically with TarP during Invasion
Abstractinfection, yet a thorough understanding of the molecular mechanisms initiating and orchestrating actin rearrangements has lagged. Our work highlights the application of genetic manipulation to address open questions regarding chlamydial invasion, a process essential to survival. We provide definitive insight regarding the role of the type III secreted effector TmeA and how that activity relates to another prominent effector, TarP. In addition, our data implicate at least one source that contributes to the functional divergence of entry mechanisms among chlamydial species.
Frontiers in Cellular and Infection Microbiology · 2023 · 31 citations · open access
Molecular pathogenesis of Chlamydia trachomatis
AbstractChlamydia trachomatis is a strict intracellular human pathogen. It is the main bacterial cause of sexually transmitted infections and the etiologic agent of trachoma, which is the leading cause of preventable blindness. Despite over 100 years since C. trachomatis was first identified, there is still no vaccine. However in recent years, the advancement of genetic manipulation approaches for C. trachomatis has increased our understanding of the molecular pathogenesis of C. trachomatis and progress towards a vaccine. In this mini-review, we aimed to outline the factors related to the developmental cycle phase and specific pathogenesis activity of C. trachomatis in order to focus priorities for future genetic approaches. We highlight the factors known to be critical for developmental cycle stages, gene expression regulatory factors, type III secretion system and their effectors, and individual virulence factors with known impacts.
Molecular Characterization of the ClpC AAA+ ATPase in the Biology of Chlamydia trachomatis
AbstractChlamydia trachomatis is an obligate intracellular pathogen and the world's leading cause of preventable infectious blindness and bacterial sexually transmitted infections. Due to the high prevalence of chlamydial infections along with negative effects of current broad-spectrum treatment strategies, new antichlamydial agents with novel targets are desperately needed. In this context, bacterial Clp proteases have emerged as promising new antibiotic targets, since they often play central roles in bacterial physiology and, for some bacterial species, are even essential for survival. Here, we report on the chlamydial AAA+ unfoldase ClpC, its functional reconstitution and characterization, individually and as part of the ClpCP2P1 protease, and establish an essential role for ClpC in chlamydial growth and intracellular development, thereby identifying ClpC as a potential target for antichlamydial compounds.
Springer Link (Chiba Institute of Technology) · 2025 · 0 citations
Current Status of Trachoma Infections and a Discussion on Treatment Approaches: A Comparative Analysis of Azithromycin and Doxycycline
AbstractChlamydia trachomatis causes a wide range of diseases, affecting the eyes, genital tract, and other organs, and can also lead to mother-to-child transmission. Genital Chlamydia trachomatis infection specifically refers to a sexually transmitted disease characterized primarily by inflammation of the urogenital tract caused by Chlamydia trachomatis. Here, a brief review of the pathogen biology research on the mechanism of action and pathogenic factors of Chlamydia trachomatis infection is provided. Additionally, through a comparative analysis of the efficacy, resistance data, administration methods, and current clinical application status of azithromycin and doxycycline, this paper reveals the advantages and limitations of the two drugs in the treatment of trachoma, with the aim of providing a basis for further research on Chlamydia trachomatis infections.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
